Researchers identified 3 distinct PsA phenotype clusters, emphasizing the importance of PsO severity in treatment decision making.

Topline data were announced from two phase 3 trials evaluating deucravacitinib in adults with active psoriatic arthritis.

Severe maternal morbidity events in first pregnancy were associated with a significantly reduced likelihood of subsequent delivery.

Patients with systemic lupus erythematosus (SLE) who test positive for antiphospholipid antibodies (aPLs) are at a significantly higher risk of developing diffuse alveolar hemorrhage (DAH), according ...

COVID-19 infection is associated with accelerated decline in kidney function, especially after hospitalization.

Significant association between rheumatoid arthritis and increased chronic obstructive pulmonary disease risk seen in both genders, seropositive/seronegative ...

Disease-modifying therapy use for MS in pregnancy is associated with certain adverse outcomes, including small for gestational age.

Despite advances, there remain gaps in the understanding of and personalized treatment for chronic pain in rheumatology, especially among women.

Higher FT4 levels were associated with increased risks for knee OA prevalence, severity, and progression, especially among patients with greater joint loading.

Upadacitinib demonstrated long-term efficacy for the treatment of ankylosing spondylitis among patients who failed to respond to prior biologic therapy.

The FDA has granted Fast Track designation to LPCN 1148 for the treatment of sarcopenia in patients with decompensated cirrhosis.

Topline data were announced from a phase 3 trial evaluating CagriSema in overweight or obese patients without type 2 diabetes.